ABL Diagnostics Société anonyme (EPA:ABLD)

Market Cap	47.37M
Revenue (ttm)	6.23M
Net Income (ttm)	463.36K
Shares Out	16.11M
EPS (ttm)	n/a
PE Ratio	102.24
Forward PE	n/a
Dividend	0.05 (1.70%)
Ex-Dividend Date	Jun 27, 2025

Volume	1,587
Average Volume	409
Open	3.000
Previous Close	3.120
Day's Range	2.720 - 3.120
52-Week Range	2.400 - 8.100
Beta	-1.11
RSI	5.73
Earnings Date	Dec 4, 2025

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and sali...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2024, EPA:ABLD's revenue was 5.87 million, a decrease of -5.16% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.